| Neutrophil–lymphocyte ratio |
| Halazun [30] | 2008 | CRLM following curative-intent resection | 440 | DFS | 2.26 (1.65−3.13) | <0.001 | 5 |
| Ding [28] | 2010 | CC following curative resection (stage IIA) | 141 | RFS | 4.88 (1.73−13.75) | 0.003 | 4 |
| Hung [29] | 2011 | CC following curative resection (stage II) | 1,040 | OS | 1.29 (1.07−1.80) | 0.012 | 5 |
| Chiang [18] | 2012 | CRC following curative resection (stage I-III) | 3,857 | DFS | 1.31 (1.09−1.57) (especially CC) | 0.013 | 3 |
| Guthrie [19] | 2013 | CRC following curative resection (stage I-III) | 206 | CSS | 3.07 (1.23−7.63) | <0.05 | 5 |
| Malietzis [20] | 2014 | CRC following curative resection (stage I-III) | 506 | DFS | 2.41 (1.12−5.15) | 0.024 | 3 |
| Nagasaki [25] | 2015 | RC following nCRT and curative resection (stage I-III) | 201 | OS | 3.38 | 0.012 | 3 |
| Li [21] | 2016 | CRC following curative resection (stage I-III) | 5,336 | DFS OS | 1.20 (1.05−1.37) 1.23 (1.01−1.50) | 0.009 0.047 | 2.72 |
| Song [23] | 2017 | CRC following resection (stage I-IV) | 1,744 | CSS OS | 0.74 (0.57−0.95) 0.76 (0.60−0.96) (reference: NLR≥2) | 0.018 0.021 | 2 |
| Pedrazzani [24] | 2017 | CRC following curative resection (stage I-IV) | 603 | CSS OS | 1.22 (0.77−1.93) 1.15 (0.86−1.54) | 0.40 0.003 | 3.5 |
| Mao [31] | 2019 | CRLM following nCT and resection | 183 | RFS OS | 1.53 (1.08−2.18) 2.43 (1.49−3.94) | 0.017 <0.001 | 2.3 |
| Casadei-Gardini [33] | 2019 | CRC following CT (stage IV) | 276 | PFS OS | 2.27 (1.59−3.23) 14.4 (11.4−17.1) | <0.001 <0.001 | 3 |
| Inamoto [22] | 2019 | CRC following curative resection (stage I-III) | 448 | DFS CSS OS | 1.71 (1.12−2.66) 2.11 (0.96−5.05) 2.04 (1.11−3.96) | 0.01 0.06 0.02 | 2.05 |
| Erstad [32] | 2020 | CRLM following curative-intent resection | 151 | OS | 2.46 (1.08−5.60) | 0.032 | 5 |
| Yosida [27] | 2020 | RC following curative resection (T1-2) | 151 | DFS | 5.11 (1.84−16.4) | 0.002 | 2.58 |
| Zhang [26] | 2020 | RC following nCRT and curative resection (stage II-III) | 472 | DFS OS | 1.71 (1.02−2.87) 1.80 (1.01−3.20) | 0.044 0.046 | 2.3 |
| Platelet–lymphocyte ratio |
| Pedrazzani [24] | 2017 | CRC following curative resection (stage I-IV) | 603 | CSS OS | 1.64 (0.74−3.62) 1.86 (1.05−3.32) | 0.22 0.034 | 350 |
| Erstad [32] | 2020 | CRLM following curative-intent resection | 151 | OS | 2.10 (1.04−4.23) | 0.037 | 220 |
| An [14] | 2022 | RC following nCRT and curative resection (stage I-III) | 168 | OS | 1.79 (1.01−3.17) | 0.047 | 170 |
| Lymphocyte–monocyte ratio |
| Li [21] | 2016 | CRC following curative resection (stage I-III) | 5,336 | DFS OS | 0.77 (0.67−0.88) 0.76 (0.62−0.93) | <0.001 0.008 | 2.83 |
| Chan [35] | 2017 | CRC following curative resection (stage I-III) | 1,623 | OS | 0.57 (0.48−0.68) | <0.001 | 2.38 |
| Chen [37] | 2019 | Obstructive CRC with stent insertion following resection | 128 | DFS OS | 0.42 (0.17−1.07) 0.40 (0.18−0.92) | 0.068 0.031 | 1.67 |
| Glasgow prognostic score |
| Choi [39] | 2014 | CRC following resection (stage I-IV) | 105 | CSS | 5.17 (1.76−15.18) | 0.003 | |
| Inamoto [22] | 2019 | CRC following curative resection (stage I-III) | 448 | DFS CSS OS | 1.68 (1.03−2.67) 2.17 (1.03−4.49) 1.73 (0.97−3.02) | 0.04 0.04 0.06 | |
| Lee [40] | 2020 | CRC following curative-intent resection (stage I-IV) | 1,590 | DFS OS | 1.71 (1.23−2.38) 2.34 (1.62−3.39) | 0.001 0.001 | |
| Modified Glasgow prognostic score |
| Leitch [43] | 2007 | CRC following curative-intent resection (stage I-IV) | 149 | CSS | 1.44 (1.01−2.04) | 0.043 | |
| Roxburgh [41] | 2009 | CRC following curative resection (stage I-III) | 287 | CSS | 2.65 (1.66−4.25) | <0.001 | |
| Park [44] | 2016 | CRC following curative-intent resection (stage I-IV) | 1,000 | CSS OS | 1.28 (1.09−1.52) 1.28 (1.13−1.45) | 0.003 <0.001 | |
| Tokunaga [42] | 2017 | CRC following curative resection (stage I-III) | 468 | RFS OS | 2.14 (1.40−3.24) 2.45 (1.53−3.88) | <0.001 <0.001 | |
| Suzuki [45] | 2018 | CRC following curative-intent resection (stage I-IV) | 727 | OS | 2.01 | 0.005 | |